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Abstract
Cancer is a complex whole-body chronic disease, is involved in multiple causes, 
multiple processes, and multiple consequences, which are associated with a series 
of molecular alterations in the different levels of genome, transcriptome, proteome, 
metabolome, and radiome, with between-molecule mutual interactions. Those 
molecule-panels are the important resources to recognize the reliable molecular 
pattern biomarkers for precise prediction, diagnosis, and prognostic assessment in 
cancer. Pattern recognition is an effective methodology to identify those molecule-
panels. The rapid development of computation biology, systems biology, and 
multiomics is driving the development of pattern recognition to discover reliable 
molecular pattern biomarkers for cancer treatment. This book chapter addresses the 
concept of pattern recognition and pattern biomarkers, status of multiomics-based 
molecular patterns, and future perspective in prediction, diagnosis, and prognostic 
assessment of a cancer.
Keywords: cancer, multiomics, genomics, transcriptomics, proteomics, 
metabolomics, radiomics, molecule-pattern biomarker, pattern recognition
1. Introduction
Cancer is a leading cause of death worldwide, with increasing morbidity and 
mortality. Studies indicated that the number of new cancer case per year will be 
19.3 million by 2025, and more than half of cancer cases and mortality occur in 
developing countries and the proportion tendency is estimated to increase by 2025 
[1]. Cancer is a complex process involving multiple causes, multiple processes, and 
multiple consequences, which are associated with a series of molecular alterations in 
the different levels of genome, transcriptome, proteome, metabolome, and radiome, 
with between-molecule mutual interactions. Cancer arises when normal cells’ orderly 
processes controlled multiplication and life span were interfered. It is also reported 
that person’s genetic makeup and lifestyle factors such as diet, alcohol, smoke, and 
physical activity, influence the rate at which cancer develops and progresses.
Alterations or mutations of genetic substance of the cells are the main cause of 
changes in cellular behavior. Dysregulation of the normal cellular procedure in can-
cer for cell fission, differentiation, apoptosis and proliferation is due to alterations 
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in multiple genes expression and leading to an imbalance between cell replication 
and cell death, which is beneficial for growth of tumor cell population [2, 3]. With 
cancer progresses, the genetic drift of the cell population generates cell hetero-
geneity with characteristics involved in cell antigenicity, invasiveness, metastatic 
potential, rate of cell proliferation, differentiation state and response to chemo-
therapeutic agents [4–6]. A study showed that the mutation of two to eight driver 
genes is sufficient for an emblematical cancer occurrence. The passenger genes are 
not oncogenic and mutation of passenger genes is unable to cause occurrence of a 
cancer [7, 8]. Therefore, attention should be paid to a panel of genetic mutations, 
named gene pattern mutation. Depending on the genetic central dogma, gene 
pattern mutation may lead to a series of alterations of messenger RNA (mRNA) and 
protein expressions. With the use of this pattern, the condition of low sensitivity 
of a single-tumor marker or low specificity of a large number of samples is reduced 
when diagnosis models are set based on differentially expressed proteins or peptides 
between tumor tissues and normal tissues [9].
A cancer biomarker is defined as a substance or biological process that can 
indicate the presence of cancer in the body, which is important for people to monitor 
personal health [10]. Physical examinations (e.g., blood pressure), biological and 
genetic tests, along with others that can be objectively detected and used as indica-
tors of pathogenic processes and alterations which may present as a result of treat-
ment, are regarded as biomarkers [11, 12]. All the alterations in the levels of DNA, 
RNA, protein, and metabolite between cancer patients and healthy people could be 
called biomarkers, and therefore in terms of source, biomarkers usually are assorted 
into different categories including genetic biomarker, epigenetic biomarker, protein 
biomarker, metabolite biomarker and immunological biomarker and so on [13]. 
Generally, biomarkers used in clinic survey and diagnosis are from the four ways:  
(i) metabolites of tumor cells, (ii) abnormal differentiation of cellular gene 
products, (iii) tumor necrosis and exfoliation of tumor cells release into the blood 
circulation, and (iv) cell reactive products of tumor host cells [9]. Most of cancer 
biomarkers are detected in the tumor tissue or in blood. In order to maximize 
usefulness and minimize cost of screening or early detection, it is advantageous to 
be able to measure biomarkers in body fluid, which can be obtained using minimally 
invasive samples, such as blood, urine, sputum or stool [10]. Biomarkers play an 
important role in cancer for precise prediction, diagnosis and prognostic assessment. 
Thereby, with the development of biomarkers, they have far-reaching significances 
for people to recognize and treat cancer as follows: (i) the understanding of molecu-
lar mechanisms of diseases, (ii) identification of possible new disease pathways, (iii) 
prediction models of complex diseases, (iv) the determination of the level of biologi-
cal activity of the disease, (v) refinement of disease phenotypes that may respond 
differently to specific treatments, (vi) the monitoring of treatment responses, 
and (vii) the potential application of precision medicine [14, 15]. However, it still 
remains a problem that biomarkers were detected after occurrence of cancer. With 
the fast development of image technology, radiomics is generated and can well solve 
that above problem. Quantitative analysis of imaging characteristics provides not 
only the tumor phenotype but also the underlying genotype information so that 
one can better diagnose and prognostic assessment for cancer patients [16]. A single 
tumor biomarker is insufficient and unreliable for precise prediction, diagnosis 
and prognostic assessment in cancer. The multi-parameter systematic strategies for 
predictive, preventive, and personalized medicine (PPPM) in cancer [4] emphasized 
that those molecule-panels, all of the differences and molecular alterations in the 
genome, transcriptome, proteome, metabolome, and radiome, with between-
molecule mutual interactions, are the important resources to identify and recognize 
the reliable molecular pattern biomarkers for precise prediction, diagnosis, and 
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prognostic assessment in cancer. Pattern recognition is an effective methodology to 
identify those molecule-panels. In fact, pattern recognition means that recognize 
molecule-pattern biomarkers, in other words, to use a set of patterns that consist of 
several biomarkers to improve the accuracy and specificity of prediction, preven-
tion, diagnosis, treatment, and prognostic assessment of tumor [9].
The rapid development of computation biology, systems biology, and mul-
tiomics is driving the development of pattern recognition to discover reliable 
molecular pattern biomarkers for cancer treatment. This book chapter addresses the 
concept of pattern recognition and pattern biomarkers, status of multiomics-based 
molecular patterns, and future perspective in prediction, diagnosis, and prognostic 
assessment of a cancer.
2. Pathophysiological basis of molecule-pattern biomarker in cancer
Cancer is a complex whole-body chronic disease, which results in a series of 
molecular alterations and associated with signal transduction system, cell cycle, 
proliferation, differentiation and apoptosis [17, 18]. Many factors are related to 
occurrence and development of a cancer.
Genomic instability plays a key role in cancer development and progression. It 
provides a way to make a cell or subset of cells gain an ability of selective advantage 
than adjacent cells, achieving outgrowth and advantages in the tissue microenviron-
ment. Genomic instability can generate aneuploid cells. Aneuploidy influences 
on the transcriptome and proteome and further results in proteotoxic stress and 
activation of the endoplasmic reticulum stress response. Consequently, aneuploidy 
can regulate features of the cells and the microenvironment [19]. In normal cells, 
the quality of reproduction of the genome at each stage of the cell cycle is protected 
by checkpoints. The existence of aneuploid cells in cancer exactly suggested one 
or more checkpoints are failed. The genomic heterogeneity might provide growth 
advantages for cancer “tissue” under selection pressure, such as hypoxia, immunity, 
and treatment-related challenges [1]. Genomic instability in cancer causes a serious 
challenge for cancer treatment.
Genetic mutations that cause cell dysfunction in most of cases support the 
development and progression of cancer. Moreover, the interaction between cancer 
cells and their environment, known as the tumor microenvironment, and their 
mutually interacted regulatory factors, can affect disease initiation and progres-
sion. The tumor microenvironment is composed of stromal cells, extracellular 
matrix (ECM), and signaling molecules that communicate with cancer cells. The 
stromal cells including endothelial cells, pericytes, fibroblasts, and immune cells, 
along with the surrounding ECM, constitute a supporting matrix for the tumor and 
regulate the tumor microenvironment. Angiogenesis and metastasis, two pivotal 
hallmarks of cancer, are modulated by the composition of the tumor microenviron-
ment. Furthermore, the tumor microenvironment is not only affected by signals 
from tumor cells, but also stromal components through influencing cancer cell 
function to promote tumor progression and metastasis [20, 21]. Therefore, tumor 
microenvironment also is an important aspect for cancer therapy.
Tumor heterogeneity is another momentous feature of malignant tumor and 
plays a vital role in development, progression, and treatment of cancer [22–26]. On 
the one hand, in most of cancer cases, heterogeneity is found that not only from 
same kind of tumor among different patients, but also in all tumor progression 
phases of the identical individual patients [27]. The genetic instability of tumor cell 
is tightly related to tumor progression and heterogeneity and leads to the presence 
of variations [28, 29]. On the other hand, tumor heterogeneity is relevant to the 
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individual differences between tumor patients. For example, the function of liver 
and kidney, age, physical condition, psychological status and personal lifestyle 
factors, are also another important factors which affect on the tumor progres-
sion and treatment [30]. A number of treatment plans of patients were designed 
according to the doctor’s experiences and adopted same therapy model for different 
cancer patients in clinic. Due to ignore tumor heterogeneity, the “one-size-fits-all” 
therapeutic model resulted in the expected curative effect could not completely 
be achieved [4]. Thereby, tumor heterogeneity is becoming an important factor to 
hinder the effective treatment and cancer research.
Molecular mechanisms of initiation and progression of a cancer do not just exist 
one kind of intracellular signal pathway [31]. Several researches have indicated that 
phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein 
kinase (MAPK) and signal transducer, and activator of transcription 3 (STAT3) 
pathways were activated in obesity-associated colon cancer. Mammalian target 
of rapamycin (mTOR) as a down-stream of both PI3K/Akt and MAPK is highly 
activated [32]. Activated mTOR in proper order inhibits the PI3K/Akt pathway 
and further activates the STAT3 pathway [33]. In case that mTOR is inhibited, the 
activity of PI3K/Akt may obviously increase owing to the feedback inhibition of 
mTOR on PI3K activity [34]. Therefore, it is necessary to simultaneously suppress 
the expressions of mTOR and PI3K for the treatment of obesity-related cancer [4]. 
Hence one can see that the interaction and interrelationship of multiple signaling 
pathways is essential to pay more attention to study, and a single signaling molecule 
or biomarker is unreliable for the prediction, diagnosis, and treatment of cancer.
So far, there are many kinds of treatments for cancer including surgery, radio-
therapy, and systemic treatments including cytotoxic chemotherapy, hormonal 
therapy, immunotherapy, and targeted therapies [35]. Personalized or individual-
ized variations are related to human healthcare, and the relationship is shown 
(Figure 1). Three primary stages, prediction/prevention, early-stage diagnosis/
early-stage therapy, and late-stage diagnosis/late-stage therapy are involved 
in human healthcare. Personalized or individualized variations can be used as 
biomarkers for prediction, and further the assessment of preventive response 
reflects the results of preventive treatments. Personalized or individualized 
variations also can be regarded as diagnostic biomarkers and further for cancer 
therapy. The assessment of therapeutic response, known as prognostic assessment, 
consists in early-stage therapy and late-stage therapy, and reveals the influence of 
therapeutic intervention. Of the three stages, prediction/prevention is the most 
significant part due to make people keep on a healthy condition and be treated in 
time once cancer occurs. Early-stage diagnosis/therapy also is better approach to 
block and repress the progression of cancer while the preventive strategy failed. 
Late-stage diagnosis/therapy is also named clinical diagnosis and treatment of a 
cancer. Unluckily, most of cancer cases were found in late stage. In order to avoid 
aforementioned problem and improve people’s health level, many researchers 
concentrate on exploration of biomarkers on prediction/prevention and early-
stage diagnosis/therapy for cancer [4]. According to functional classification, 
biomarkers are divided into two categories (Table 1): (i) serving for the mecha-
nism and therapeutic targets, and (ii) devoting to prediction, diagnostic test, and 
prognosis assessment. The first kind of biomarkers is relevant to the initiation and 
development of disease, and directly indicates the mechanism and pathogenesis of 
the disease. Commonly, it is pivotal site in cell signal pathways, like P53 in naso-
pharyngeal carcinoma (NPC) [36]. Another kind of biomarkers does not need to 
be causal to the occurrence and development of the disease, but requires to be pro-
vided with specificity and a certain number of changes to be easily detected. Based 
on Bayes’ rule, three or more key molecules can form molecule-pattern biomarker 
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to improve the accuracy of cancer diagnosis and therapy [9, 37]. In summary, due 
to the complex pathophysiological basis of cancer, recognition of molecule-pattern 
biomarker for precise prediction, diagnosis, and prognostic assessment in cancer 
is an urgent demand to study and further close to realize precision medicine (PM) 
and PPPM.
3.  Methodology of recognition of multiomics-based pattern biomarkers 
in cancer
Based on central dogma, genetic changes influence the RNA expression, and 
cause the alterations of proteins, along with taken into account the changes of 
metabolite and tumor heterogeneity, all above variations in genome, transcrip-
tome, proteome, metabolome, and radiome are measured with corresponding 
omics methodology including genomics, transcriptomics, proteomics, metabolo-
mics, and radiomics. Multiomics-generated biomarkers can make up integrative 
molecule-pattern biomarkers and pattern recognition for cancer treatment. This 
section mainly addresses the previous mentioned five omics approaches com-
bined with computation biology and systems biology contribute to the develop-
ment of cancer precise medicine (Figure 2) [9].
Types Definition Application
Type I This type of biomarker exist a causal relationship with disease, 
associate with the initiation and development of disease, and 
can directly address the pathogenesis of disease.
Contribute to the 
mechanism and therapeutic 
targets of disease.
Type II This type of biomarker does not need a causal relationship 
with the occurrence and development of disease, but requires 
specificity and a certain amount of change to be easily detected.
Contribute to the 
prediction, diagnosis, and 
prognostic assessment.
Table 1. 
Concept and categories of biomarkers [9].
Figure 1. 
Variations involved in each aspect of healthcare. Reproduced from Hu et al. [4], with permission from BioMed 
Central open access article, copyright 2013.
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3.1 Genomics
The development of genomics drives the understanding and cognition of 
cancer. The development of gene sequencing technology is a significant advance-
ment in the field of scientific research. First, based on the method of the previous 
“plus and minus,” Sanger modified and invented the “dideoxy method” for DNA 
sequencing in 1977 [38–40]. Sanger sequencing acquired many achievements and 
completed a great work “Human Genome Project.” Nevertheless, high cost and low 
throughput are disadvantages of Sanger sequencing technology [41, 42]. The limit 
of Sanger sequencing promotes the progression and generation of new sequencing 
technology. The second-generation sequencing technology has many advantages 
including higher speed and throughput, higher degree of parallelism, effective uti-
lization of reagents and so on. However, problems still exist, such as the reduction 
of accuracy of sequencing and relatively higher cost [43, 44]. Due to the presence 
of shortcomings of the second-generation sequencing technology, the next-
generation sequencing (NGS) requires to be discovered. The third-generation of 
sequencing technology is found to make up for the deficiency of second-generation. 
For example, PacBio RS and Oxford Nanopore sequencing not only possess funda-
mental character of the single molecule sequencing, do not need any polymerase 
chain reaction (PCR) process, availably avoid the PCR bias caused by the system 
error, and well improve the read length, but also keep the high-throughput and low 
cost of the second-generation technology [45]. Research demonstrates that accu-
mulation of genomic alternations leads to the occurrence of cancer, which involves 
small insertions and deletions, base substitutions, copy number alterations (CNA), 
chromosomal rearrangements, and microbial infections [46]. Besides, a number of 
polymorphic CNAs have been discovered in the human genome [47]. DNA micro-
arrays, also named as “gene chip” or “DNA chip,” obtained a great success that 
could monitor tens of thousands of one time expression and hundreds of thou-
sands of genes. Single nucleotide polymorphisms (SNPs) are the most common 
form of DNA variation in the human genome, approximately occurring one time 
every 100–300 bases [48]. Many studies suggested SNPs might affect the activity 
Figure 2. 
Different levels of omics-based pattern biomarkers. Modified from Cheng and Zhan [9], with permission from 
Springer open access article, copyright 2017.
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of metabolism-related key enzyme, therefore generating effects on tumor progres-
sion and drug efficacy. However, with in-depth research, scientists indicated one 
SNP or a simple CNA could not influence the whole development of the individual 
process of cancer. The occurrence of a cancer is a result of changes of multiple 
sites, thus current study is shifting towards several genetic mutation patterns 
[9]. In addition, breakthrough progress has been made in strategies for obtaining 
DNA information of tumor tissues. Currently, a novel method found to collect 
DNA information of tumor tissue is called circulating tumor cell (CTC), which 
is a general term for all tumor cells in peripheral blood [49]. Compared to tumor 
tissue samples, blood specimens possess more advantages such as less invasive, easy 
to acquire, and can be collected repeatedly. It is a typical source of specimens and 
convenient to operate in clinical practice, so that significantly improves the value 
of aforementioned method [9]. Circulating tumor DNA (ctDNA) means a tumor 
cell body that is apoptotic by shedding or released into the circulatory system, 
and rapid development of gene sequencing results in that it is able to detect in the 
blood [50]. Therefore, ctDNAs are possible to find key mutation sites and served as 
biomarkers. Over the past few years, liquid biopsy combined with ctDNA analysis 
is helpful and beneficial for the molecular diagnosis and monitoring of cancer. 
Moreover, BEAMing (emulsion, amplification, beads, and magnetics) and CAPP-
seq (cancer personalized profiling by deep sequencing) are discovered and used to 
quantify ctDNA in blood [51, 52]. Furthermore, there are several unknown things 
about ctDNA including its size, existing form, mechanisms of released into blood 
stream, and its degradation rate in blood [53]. In summary, the development of 
genomics provides the method, important information about genome, and impact-
ful biomarkers for diagnosis of cancer and drives the progress of cancer genomics.
3.2 Transcriptomics
Based on the genetic central rule, DNA through self-replication and transcripts 
to form the mRNAs, and finally translates to be a protein. The mRNA is served as a 
bridge between gene and protein in biological process and linked genome and phe-
notype. Once variation of gene sequence of mRNA occurs, the amino acid sequence 
of the protein will be correspondingly altered. Therefore, the understanding of 
transcriptomics is important for addressing functional elements of the genome and 
cognizing the development of cancer. The key goal of transcriptomics is to classify 
all types of transcripts, reveal the transcriptional structure of the genes, and quan-
tify the expression levels of each transcript during development and under different 
conditions. Nowadays, many methods are generated to be used for the study of tran-
scriptome, such as hybridization-or sequence-based approaches [54]. In general, the 
way of nucleic acids with hybridization-based is incubation of fluorescently labeled-
complementary DNA (cDNA) from reverse transcription of different mRNAs with 
a microarray contained genes of interest, then digitized with a dedicated scanner 
and image analysis and finally gene name, clone identifier, and intensity values are 
acquired [55]. Furthermore, genomic tiling microarrays are found to provide a more 
unerring opinion of the transcriptional activities within a genome [56]. Howbeit, 
there are some disadvantages, like relying on the current knowledge of genome 
sequence, high background levels owing to cross-hybridization, and both back-
ground and saturation of signals resulted in a limited dynamic range of detection 
[57, 58]. Sequence-based strategy is able to detect cDNA sequence but not depend on 
the probes. With the development of high-throughput DNA sequencing technique of 
NGS, a new method used for mapping and quantifying transcriptome is occurred, 
named RNA-seq. It possesses a lot of advantages, for instance, high throughput, 
high sensitivity, high resolution, and no reconstructions. RNA-seq is able to analyze 
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the whole transcriptome of any species, including detection of unknown genes or 
transcripts, exact identification of the cleavage site, and a variable SNP or untrans-
lated region (UTR region) [16]. In another hand, the research field of noncoding 
RNA (ncRNA) should be paid more attention. The ncRNAs consist of tRNA, rRNA, 
snoRNA, snRNA, piRNA, miRNA, and lncRNA [59]. Of them, miRNA and lncRNA 
are familiar and studied more. MicroRNAs, with a sequence of approximately 
21 bp, are a kind of small ncRNAs, which take part in multiple cellular functions 
including proliferation, differentiation, metabolism and apoptosis [60]. In general, 
TaqMan-based real-time quantitative PCR (RT-qPCR) with separate microRNA-
specific primers and probes is used to detect the expression levels of microRNAs. 
The expression of microRNAs is frequently dysregulated in a cancer-specific manner 
so that microRNAs are potential to be biomarkers for cancer detection. Many studies 
demonstrated the microRNAs as biomarkers for prediction, diagnosis, and prog-
nosis for cancer [9]. However, current studies on the function of miRNAs have not 
yet been fully understood, previous studies of miRNAs have found different types 
of miRNAs and their effects on oncogenesis and gene expression level of miRNA as 
antioncogene. In addition, it is predicted that about 30% of protein-encoding genes 
are regulated by miRNAs [61, 62]. lncRNAs execute multiple functions in cells and 
are reported as biomarkers in many types of cancers, like breast, lung, gastric, liver, 
and prostate cancers [63]. The lncRNAs play a vital role in recognition and treatment 
of cancer. Up to now, the biological effects of lncRNAs are still incompletely clear, 
but they have already been found to be prolific regulators of many cell processes. 
Several lncRNAs overlap with gene promoters, thus transcription of these lncRNAs 
might interfere with nucleosome-deleted regions and histone modifications of 
nucleosomes in those promoters [64, 65]. Moreover, detection of lncRNA is easily 
influenced by anticoagulant such as EDTA, and lncRNA is lightly degraded by other 
substance of the blood so that it cannot be preserved for a long time. More researches 
are necessary to solve these problems in the future [9].
3.3 Proteomics
Proteins are most direct phenotype characteristics of DNA in biological system. 
Proteins are related to multiple cellular mechanisms including cell motility, cell 
growth, cell signaling, and protein metabolic process [66]. The study of proteome 
is beneficial to the understanding of cancer. The aim of proteomics is to identify 
proteins and construct protein pathways and networks to characterize information 
and ultimately understand the functional relevance of proteins in cells or organisms 
[67]. The proteome is one of the most complex omes among genome, transcriptome, 
and proteome. The amount of human proteins and their variants or protein species 
are approximately reached to billions [4]. Furthermore, one gene is corresponded 
to multiple proteins, known as one gene-multiple proteins model, not one gene-one 
protein model so that the complexity of proteome is conceivable [68, 69]. So far, 
only the sequence and copy number of DNAs and RNAs in a genome are able to 
measure with current technologies. However, a lot of information can be acquired 
in a proteome, including amino acid sequence, copy number, splicing, variants, 
post-translational modifications (PTMs), spatial conformation, and spatial re-
distribution [16]. Proteomics mainly applies to the detection, identification, and 
quantification of the protein in a defined system (cell, tissue, organ, and organelles). 
Of detection technologies, gel and gel-free methods are used [68, 69]. Two-
dimensional gel electrophoresis (2DGE), two-dimensional difference in gel electro-
phoresis (2D DIGE), and one-dimensional gel electrophoresis (1DGE) are mainly 
involved in gel-based methods [69, 70]. When ones want to detect a certain variants 
of a given protein or a kind of PTM with gel-based methods, a specific antibody is 
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necessary to be used [70–72]. Gel-free methods primarily have hydrophobic interac-
tion chromatography (HIC) to separate large bio-molecules, like proteins, C4 or C5 
reverse phase liquid chromatography (RPLC) with 300 Å pore-size particles, capil-
lary electrophoresis (CE)-electrospray ionization-mass spectrometry (CE-ESI-MS), 
multiplexed gel-eluted liquid fraction entrapment electrophoresis (mGELFrEE; 
size-based separation) with 8 parallel glass gel column, and weak-cation exchange 
chromatography (WCX) in combination with HIC in a single column with a single 
phase (2D-LC; from WCX to HIC mode) [73–80]. Mass spectrometry (MS) plays 
an important role in identification of protein variants and PTMs, because the amino 
acid sequence of complete proteins, splicing sites and PTM-sites are able to be deter-
mined with MS [69, 71, 81, 82]. Tandem mass spectrometry (MS/MS) can detect 
amino acid sequence of a protein, and directly authenticate the errors of amino 
acid sequence, variations, and modifications, which causes character of PTMs and 
protein variants with different types of mass spectrometers, for instance, matrix-
assisted laser desorption ionization-time of flight-time of flight (MALDI-TOF-TOF), 
LTQ Orbitrap system, triple TOF 5600 or 6600 systems and Fourier transform ion 
cyclotron resonance (FTICR) with different types of ion fragmentation models 
including electron capture dissociation (ECD), electron transfer dissociation (ETD) 
and collision induced dissociation (CID). Different types of samples and research 
objectives should use identification techniques that are appropriate for them [80]. 
Quantification of protein is necessary to clarify their biological significance, which 
is detected with three main methods, including 2DGE-based quantitative methods, 
label-free quantitative techniques like sequential window acquisition of all theo-
retical mass spectra (SWATH) and selected/multiple reaction monitoring (SRM/
MRM), and stable isotope-labeled quantitative approaches including isobaric tags 
for relative and absolute quantification iTRAQ [80]. Furthermore, combined with 
structural proteomics maybe is better for understanding the biological functions 
in biological systems [83, 84]. Also, the study of the protein-protein interaction 
analysis and cell signal pathways has become a hot topic. The identification of 
protein-protein interactions is meaningful for understanding signal transduction 
mechanisms and establishing intracellular signaling networks [4]. Under patho-
logical conditions, the body can secrete several special proteins owing to the other 
mRNA synthesis and alternative chromosomal genetic variations involved cancer, 
diabetes and Alzheimer disease [85]. Therefore, protein is able to be a biomarker and 
proteomics is an important strategy for the study of cancer.
3.4 Metabolomics
Metabolites and proteins are equally important to understand cancer. Metabolites 
are small molecules (<1 KDa) produced by metabolism, which can provide func-
tional information that is not directly available from the genome and proteome 
in cellular and tissue states [86, 87]. Metabolites are derived from lipids, sugars, 
proteins, and nucleic acids in a given biological system, cell, tissue, or body-fluid 
[88–90]. The alteration in metabolites is relevant to multiple factors, such as genetic, 
environment, internal, external, drug, and dietary factors. These metabolic profiles 
are related to the whole biochemical processes that are the starting, intermediate 
or final products and provide complex interactions information between the genes 
and the environment of a given condition [91, 92]. Metabolites may be capable of 
reflecting physiological and pathological processes and monitoring the progres-
sion of a disease, and are helpful to predict, diagnose, and treat [93]. Therefore, 
metabolomics is a methodology used to study metabolome, refers to identification 
of biochemical and molecular features of metabolome, among different metabo-
lite interactions between genetic/environmental factors and metabolites, and to 
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assessment of biochemical mechanisms associated with a given conditions like 
different pathophysiological processes [94]. Generally, two strategies, targeted and 
untargeted methods, are mainly employed to detect variations in a metabolome [95, 96]. 
Targeted metabolomics method concentrates on quantification of the variations of 
the hypothesis-driven known metabolite profiling (like metabolites that are pro-
duced from one or more unknown pathways) between or among groups, followed 
by multivariate statistical analysis and establishment of mathematical model [95, 
97]. Up to now, the familiar techniques used for targeted metabolomics are the triple 
quadrupole mass spectrometry (QqQ-MS) in the SRM/MRM modes with optimized 
sample extraction and liquid chromatography-mass spectrometry (LC-MS) condi-
tions [98, 99]. The untargeted metabolomics is different from targeted method, 
which shows in these aspects, such as no hypothesis-driven strategy, and the whole 
comprehensive study variations of metabolome in a biological system without bias 
for exploration of metabolite biomarkers for impactful prediction, diagnosis, and 
prognostic assessment [80, 96]. The current techniques used to qualify and quantify 
the metabolomic variations are nuclear magnetic resonance (NMR)-based methods 
and mass spectrometry (MS)-based methods [88, 100–102]. NMR-based methods 
involve one-dimensional NMR (1D-NMR), two-dimensional NMR (2D-NMR), and 
three-dimensional NMR (3D-NMR). The way to provide chemical structural and 
molecular environment information is utilizing the interaction of spin active nuclei 
(13C, 1H, 31P, 19F) with electromagnetic fields [100, 101]. NMR-based methods pos-
sess many advantages, including nondestruction of sample, minimal sample prepa-
ration, high reproducibility, relative high throughput, availability of databases, and 
availability of molecular dynamic and compartmental information with diffusional 
methods. However, overlapping of metabolites, low sensitivity, and high instrumen-
tation cost are its disadvantages [103]. MS-based methods include direct injection 
coupled with MS (DIMS), LC-MS, gas chromatography coupled with MS (GC-MS), 
capillary electrophoresis coupled with MS (CE-MS), and ion mobility coupled with 
MS (IM-MS) [80]. Aforementioned five MS-based methods have its advantages and 
limitations, and proper combination helps ones to better study. In clinic, in order to 
measure variations in a metabolome, the biological samples are extremely complex, 
including cell, tissue extracts and body-fluid. Serum/plasma and urine are com-
monly used body-fluid for metabolomics analysis in all diseases because they are 
very easily acquired and prepared, and almost no injury for patients [88, 104, 105]. 
Additionally, many researches have reported that cerebrospinal fluid (CSF), saliva, 
exhaled air, tears, and synovial fluid are likely to be regarded as biomarkers for a 
specific disease [80]. Metabolites are important source of biomarkers, and metabo-
lomics methods reasonably adopted are beneficial to predict, diagnose, and evaluate 
for cancer.
3.5 Radiomics
Medical imaging technologies, including computed tomography (CT), positron 
emission tomography (PET), and magnetic resonance imaging (MRI), are vital to 
diagnose and check after treatment for cancer. Medical images provide ones with a 
number of information about tumors, which include location and volume of tumor, 
probable measurements of diameter, the overall and marginal morphology of the 
lesion, the relationship with surrounding tissues, internal heterogeneity, CT and 
PET/CT values, MRI signal height and other values. This information is instructive 
for the diagnosis of tumors and the decision-making of clinical treatment. However, 
it is not able to accurately reflect the morphological and behavioral complexities of 
a tumor, with limitation in the assessment of treatment sensitivity and prognosis 
[106]. With the rapid development of technology, emerging discipline- radiomics 
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has occurred. Based on excellent computer technology and advanced statistical 
methods, radiomics achieves high-throughput extraction and conversion of quanti-
tative features of medical data, and make it serve for clinic decision of cancer [16]. 
Radiomics has enabled medical imaging to achieve a qualitative to quantitative 
transition and provides guidance for clinical treatment, and a large amount of data 
has the potential to develop into biomarkers that contribute to further research in 
cancer.
4. Application of pattern biomarker for PPPM or PM in cancer
Based on the development of multiomics technology, a series of molecular 
alterations in the levels of genome, transcriptome, proteome, metabolome, and 
radiome are possible to be detected and measured, which also offer many kinds 
of potential biomarkers to ones and are beneficial to well understand and study 
for cancer. In order to improve the treatment effect and approach PPPM or PM in 
cancer, the methodology of recognition of multiomics-based molecule-pattern 
biomarker is presented. The concept “pattern biomarker” refers to several biomark-
ers make up a pattern for precise prediction, diagnosis, and prognostic assessment 
in cancer, which can be derived from genome, transcriptome, proteome, metabo-
lome, or radiome, and each pattern biomarker is able to be used as a biomarker 
for recognition, therapy, and other-related research of cancer. Many researches 
prove that the use of more biomarkers can increase the accuracy of understand-
ing for cancer. For instance, based on somatic cell gene copy number aberrations, 
the alterations of gene expression analyzed with genomic and transcriptomic data 
and long-term clinical outcomes indicated several potentially important targeted 
therapeutic response-related events and mentioned a novel molecular classification 
of breast cancer patients [107]. Genomic combined with proteomic data analysis 
revealed that PI3K pathway aberrations are popular in hormone receptor-positive 
breast cancer, which provides new idea for clinically targeted therapy [108]. Tissue 
transcriptomics and urine metabolomics integrated analysis identified four urinary 
biomarkers that are more reliable compared to biomarkers derived from single omics 
Figure 3. 
Application of pattern biomarker in personalized medicine or precision medicine.
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[109]. Comprehensive analysis of transcriptomic and proteomic data suggested a 
highly significant enrichment of gonadotropin-releasing hormone (GnRH) signal-
ing pathway that was not deciphered with single omics dataset in glioblastomas, 
which proved the necessity of multiomics research [110]. In addition, the failure of 
sorafenib-treated HCCs was employed with an integrated quantitative proteomics 
and phosphoproteomics analysis, and found that the targeted drug can effectively 
inhibit its target kinase in Raf-Erk-Rsk pathway, but the downstream targets of 
Rsk-2 (eIF4B, filamin-A, and so on) were not affected, suggesting that they may be 
replaced by another active pathway and lead to treatment failure [111]. However, 
there are also many challenges needed to be faced. Considering the tumor heteroge-
neity, individual difference, different stages of tumor development, the recurrence 
of tumor, and so on, one designs an ideal model for prediction, prognosis, and 
prognostic assessment of cancer in order to further realize PPPM or PM (Figure 3).
5. Conclusion
Cancer is a complex whole-body chronic disease, is involved in multiple causes, 
multiple processes, and multiple consequences. On the contrary, the complexity of 
cancer exactly provides ones with more opportunities for PPPM or PM in cancer. 
The rapid development of genomics, transcriptomics, proteomics, metabolomics, 
and radiomics in combination with advanced computation biology and systems 
biology drives the development of pattern recognition to find reliable and effective 
molecular pattern biomarkers for cancer treatment, and further achieves PPPM or 
PM. Multiomics integration analysis is beneficial to better understand cell malig-
nant transformation and tumor progression, clarify molecular mechanisms of a 
cancer, discover novel biomarkers and targeted drugs, and improve the effect of 
targeted therapies.
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Acronyms and abbreviations
CAPP-seq  cancer personalized profiling by deep sequencing
cDNA  complementary DNA
CE  capillary electrophoresis
CE-MS  capillary electrophoresis coupled with MS
CE-ESI-MS  capillary electrophoresis-electrospray     
 ionization-massspectrometry
CID  collision induced dissociation
CNA  copy number alterations
CSF  cerebrospinal fluid
CT  computed tomography
CTC  circulating tumor cell
ctDNA  circulating tumor DNA
DIMS  direct injection coupled with MS
ECM  extracellular matrix
ECD  electron capture dissociation
ETD  electron transfer dissociation
FTICR  Fourier transform ion cyclotron resonance
GC-MS  gas chromatography coupled with MS
GnRH  gonadotropin-releasing hormone
HIC  hydrophobic interaction chromatography
lncRNAs  long noncoding RNAs
IM-MS  ion mobility coupled with MS
iTRAQ  isobaric tags for relative and absolute quantification
LC-MS  liquid chromatography-mass spectrometry
MAPK  mitogen-activated protein kinase
mGELFrEE  multiplexed gel-eluted liquid fraction entrapment   
 electrophoresis
mRNA  messenger RNA
MS  mass spectrometry
MALDI-TOF-TOF matrix-assisted laser desorption ionization-time of flight-  
 time of flight
MRI  magnetic resonance imaging
mTOR  mammalian target of rapamycin
ncRNA  noncoding RNA
NGS  next-generation sequencing
NMR  nuclear magnetic resonance
NPC  nasopharyngeal carcinoma
1DGE  one-dimensional gel electrophoresis
PCR  polymerase chain reaction
PET  positron emission tomography
PM  precision medicine
PPPM  predictive, preventive, and personalized medicine
PI3K/Akt  phosphoinositide 3-kinase/protein kinase B
PTMs  post-translational modifications
QqQ-MS  quadrupole mass spectrometry
RPLC  reverse phase liquid chromatography
RT-qPCR  real-time quantitative PCR
SNPs  single nucleotide polymorphisms
STAT3  signal transducer, and activator of transcription 3
SWATH  sequential window acquisition of all theoretical mass   
 spectra
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SRM/MRM  selected/multiple reaction monitoring
1D-NMR  one-dimensional NMR
2D-NMR  two-dimensional NMR
3D-NMR  three-dimensional NMR
2DGE  two-dimensional gel electrophoresis
2D DIGE  two-dimensional difference in gel electrophoresis
MS/MS  Tandem mass spectrometry
UTR region  untranslated region
WCX  weak-cation exchange chromatography
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